EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mineralys Therapeutics's Enterprise Value is $674.10 Mil.
Mineralys Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-81.17 Mil. Therefore, Mineralys Therapeutics's EV-to-FCF for today is -8.30.
The historical rank and industry rank for Mineralys Therapeutics's EV-to-FCF or its related term are showing as below:
MLYS'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.62 Med: 0 Max: 0
Current: -8.3
MLYS's EV-to-FCF is ranked worse than 100% of 389
companies
in the Biotechnology industry
Industry Median: 6.49
vs MLYS: -8.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mineralys Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Mineralys Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's EV-to-FCF falls into.
Mineralys Therapeutics's current Enterprise Value is $674.10 Mil.
Mineralys Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mineralys Therapeutics's PE Ratio for today is calculated as:
Mineralys Therapeutics's share price for today is $13.52.
Mineralys Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mineralys Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Mineralys Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Mineralys Therapeutics (Mineralys Therapeutics) Business Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MLYS has been successfully added to your 